Perioperative topical bovine thrombin exposure is not associated with hemodialysis graft thrombosis

Kidney International

Volumn 64, Issue 2, 2003, Pages 690-696

  Vannorsdall, Mark D ^b   Arkel, Yale S ^b   Ku, De Hui ^b   Lucas, F Lee ^b   Himmelfarb, Jonathan ^a  

^a MAINE MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antithrombin antibodies; Hemodialysis; PTFE graft; Thrombin; Thrombosis

Indexed keywords

ANTIBODY; PROTEIN PRECURSOR; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; VASCULAR ACCESS;

EID: 0037781753     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00115.x     Document Type: Article

References (30)

1. HAKIM RM, HIMMELFARB J: Hemodialysis access failure: A call to action. Kidney Int 54:1029-1040, 1998
2. SCHMITZ PG, MCCLOUD LK, REIKES ST, et al: Prophylaxis of hemodialysis graft thrombosis with fish oil: A double-blind, randomized, prospective trial. J Am Soc Nephrol 13:184-190, 2001
3. SREEDHARA R, HIMMELFARB J, LAZARUS JM, HAKIM RM: Antiplatelet therapy in graft thrombosis: Results of a prospective, randomized double-blind study. Kidney Int 45:1477-1483, 1994
4. HIMMELFARB J, VANNORSDALL M: Pharmacologic approaches to preventing hemodialysis access failure, in Hemodialysis Vascular Access, edited by SCHWAB SJ, CONLON PJ, NICHOLSON ML, Oxford, Oxford University Press, 2001
5. SCHWAB SJ, OLIVER MJ, SUHOCKI P, MCCANN R: Hemodialysis arteriovenous access: Detection of stenosis and response to treatment by vascular access blood flow. Kidney Int 59:358-362, 2001
6. MARTIN LG, MACDONALD MJ, KIKERI D, et al: Prophylactic angioplasty reduces thrombosis in virgin ePTFE arteriovenous dialysis grafts with greater than 50% stenosis: Subset analysis of a prospective randomized study. JVIR 4:389-397, 1999
7. SANDS JJ, JABYAC PA, MIRANDA CL, KAPSICK BJ: Intervention based on monthly monitoring decreases hemodialysis access thrombosis. ASAIO J 45:147-150, 1999
8. MCCARLEY P, WINGARD RL, SHYR R, et al: Vascular access blood flow monitoring reduces access morbidity and costs. Kidney Int 60:1164-1172, 2001
9. STEHMAN-BREEN CO, SHERRARD DJ, GILLEN DL, CAPS MT: Determinants of type and timing of initial permanent hemodialysis vascular access. Kidney Int 57:639-645, 2000
10. GIBSON KD, CAPS MT, KOHLER TR, et al: Assessment of a policy to reduce placement of prosthetic hemodialysis access. Kidney Int 59:2335-2345, 2001
11. SANDS JJ, NUDO SA, ASHFORD RG, et al: Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis 35:796-801, 2000
12. ZEHNDER JL, LEUNG LLK: Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 76:2001-2016, 1990
13. RAPPAPORT SI, ZIVELIN A, MINOW RA, et al: Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Path 97:84-91, 1992
14. GARGAN PE, GAFFNEY PJ, PLEASANTS JR, PLOPLIS VA: A monoclonal antibody which recognizes and epitopic region unique to the intact fibrin polymeric structure. Fibrinolysis 7:275-283, 1993
15. CHETAILLE P, ALESSI MC, KOUASSI D, et al: Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 83:902-905, 2000
16. GRAY RJ, SACKS D, MARTIN LG, TREROTOLA SO: Reporting standards for percutaneous interventions in dialysis access. JVIR 10:1405-1415, 1999
17. WINDUS DW, JENDRISAK MD, DELMEZ JA: Prosthetic fistula survival and complications in hemodialysis patients: Effects of diabetes and age. Am J Kidney Dis 19:448-452, 1992
18. BURGER H: Long-term outcome of different forms of vascular access, in Hemodialysis Vascular Access: Practice and Problems, edited by CONLON PJ et al, Oxford, Oxford University Press, 2000, p 59
19. GIBSON KD, GILLEN DL, CAPS MT, et al: Vascular access survival and incidence of revisions: A comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study. J Vasc Surg 34:694-700, 2001
20. SCHWAB SJ, HARRINGTON JT, SINGH A, et al: Vascular access for hemodialysis. Kidney Int 55:2078-2090, 2002
21. ORTEL TL, MERCER MC, THAMES EH, et al: Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 233:88-96, 2000
22. BAJZAR L: Thrombin activatable fibrinolysis inhibitor and an anti-fribronlytic pathway. Arterioscler Thromb Vasc Biol 20:2511-2518, 2000
23. BOUMA BN, MARX PF, MOZNIER LO, et al: Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 101:329-354, 2001
24. VON DEM BORNE PAK, BAJZAR L, et al: Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor dependent inhibition of fibrinolysis. J Clin Invest 99:2323-2327, 1997
25. BROZE G JR, HIGUCHI DA: Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and premature lysis of clots from hemophyilic plasma. Blood 88:3815-3823, 1996
26. FRANCIS CW, CONNAGHAN DG, SCOTT WL, MARDER VJ: Increased plasma concentration of cross-linked fibrin polymers in acute myocardia infarction. Circulation 75:1170-1177, 1987
27. FRANCIS CW, CONNAGHAN DG, MARDER VJ: Assessment of fibrin degradation products during fibrinolytic therapy for myocardial infarction. Circulation 74:1027-1036, 1986
28. CROCCO F, CRISTIANO G, SCRIVANO P, SPROVIERI M: "TpP": A new marker in the early diagnosis of acute thrombotic and embolic diseases. Clin Ter 152:145, 2001
29. LACAPRA S, ARKEL YS, KU DH, et al: The use of thrombus precursor protein, D dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism. Blood Coagul Fibrinol 11:371-377, 2000
30. ARKEL YS, PAIDAS MJ, KU DHW: The use of coagulation activation markers (soluble fibrin polymer (TpPTm), prothrombin fragment 1.2, thrombin/antithrombin, and D dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coagul Fibrinol 13:1-7, 2002